Pharmaceutical M&A exceeded 2014 total deal value in Q1 2015 and deal-making opportunities continue, as covered in this Merrill webinar.
The pharma M&A boom that kicked off Q1 2015 with 35 life sciences deals totaling $166.3 billion shows no signs of slowing, reveals an expert panel on June 24, 2015, moderated by Merrill Corporation Senior Director, Richard Martin.
In the Merrill webinar Pharma M&A Boom—Understanding the Prescription for Success, our expert panel covers:
- Forces behind increased deal activity for large and small pharma companies—and the focus of pharma investment activity.
- How multi-billion dollar bids from Pfizer and AbbVie will impact the middle market for pharmaceuticals.
- What investors are looking for now in the life sciences sector—and the biggest opportunity set in life sciences.